Cognitive Training for Cancer-related Cognitive Impairment: A Multi-Center Randomized Controlled Trial
Project Number5R01CA276222-03
Contact PI/Project LeaderVON AH, DIANE MARIE Other PIs
Awardee OrganizationOHIO STATE UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
The goal of this project is to determine the efficacy of computerized cognitive training for breast cancer
survivors (BCS) suffering from cancer-related cognitive impairment (CRCI). For millions of cancer survivors,
CRCI is a prevalent, severe, and persistent problem that negatively impacts work outcomes (work ability and
productivity), health perception, and health-related quality of life. Evidence suggests that up to 75% of the more
than 3.8 million BCS in the U.S. will experience cognitive changes that may persist for years after treatment
ends. Unfortunately, the scientific basis for managing these cognitive changes in cancer survivors is extremely
limited. Available evidence from pilot studies, including our own work, suggests that computerized cognitive
training, which is based on the principles of neuroplasticity (ability of brain neurons to re-organize and form
new neural networks), may be a viable treatment option. However, previous trials to date have been limited by
lack of attention-controlled designs, small samples, and limited follow-up. Therefore, to overcome limitations of
past studies and build on our pilot results, the purpose of this 2-group, double-masked, randomized controlled
trial is to conduct the first full-scale efficacy trial to compare computerized cognitive training (BrainHQ) to
computerized active attention control (Sudoku, crossword, word find, etc.) in BCS. Specific aims are to: (1)
test the efficacy of computerized cognitive training on improving perceived cognitive function immediately post-
intervention and over time, compared to active attention control; (2) test the efficacy of computerized cognitive
training on cognitive performance over time compared to attention control; and (3) explore transfer effects on
real-world, everyday outcomes including work-related outcomes and health-related quality of life over time
compared to active attention control. This proposal has been peer-reviewed and endorsed by the NRG
Oncology Research Base of the NCI Community Oncology Research Program (NCI NCORP) and the
NCI Division of Cancer Prevention has approved NRG Oncology to conduct the trial at their affiliated
sites. A total of 386 eligible BCS will be identified and consented through the NCI NCORP and NCI National
Clinical Trials Network (NCTN) sites, composed of over 2,000 participating locations including community and
minority clinical oncology sites. Outcomes will be collected at four time points: baseline, prior to intervention
(T1), immediately post-intervention (T2), 3 months (T3), and 6 months (T4) post-intervention. Data will be
analyzed using linear mixed models for repeated measures. The current proposal responds directly to the NCI
Notice of Special Interest to test interventions designed to address the adverse aging-related effects of cancer
and cancer treatments, builds on our previous pilot studies while also making methodological improvements,
and leverages access to all NCORP sites. Therefore, this will be the first full-scale study to test computerized
cognitive training in cancer survivors with CRCI and provide empirical evidence for clinicians’
recommendations and survivors’ treatment selections for managing cognitive impairment.
Public Health Relevance Statement
PROJECT NARRATIVE
This double-masked randomized controlled trial will leverage the NCI National Community Oncology Research
Program (NCI NCORP) and NCI National Clinical Trials Network (NCTN) sites to conduct the first national, full-
scale test of a computerized cognitive training program (BrainHQ) against a computerized active attention
control program to improve self-reported (perceived) and objective (performance) cognitive functioning as well
as examine its impact on other real-world, everyday outcomes in breast cancer survivors with cancer and
cancer treatment-related cognitive impairment. Positive or negative findings about this easily accessible
therapeutic treatment option will help provide evidence to guide clinicians’ recommendations and survivors’
treatment selections for managing this prevalent, persistent, disruptive, and often debilitating problem.
No Sub Projects information available for 5R01CA276222-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA276222-03
Patents
No Patents information available for 5R01CA276222-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA276222-03
Clinical Studies
No Clinical Studies information available for 5R01CA276222-03
News and More
Related News Releases
No news release information available for 5R01CA276222-03
History
No Historical information available for 5R01CA276222-03
Similar Projects
No Similar Projects information available for 5R01CA276222-03